替尔泊肽治疗肥胖的疗效观察与机制探讨

Obesity has become an increasingly severe global public health issue, necessitating effective therapeutic strategies. Tirzepatide, as a novel pharmaceutical agent, offers new hope for obesity treatment. This article reviews the efficacy and mechanisms of tirzepatide in obesity management. In terms of efficacy, multiple clinical trials have demonstrated that tirzepatide can significantly reduce body weight in obese patients, exhibiting superior weight-loss effects compared to traditional treatment methods. It achieves substantial weight reduction over specific periods and excels in improving obesity-related metabolic parameters, such as blood glucose and lipid profiles. Regarding the mechanism of action, tirzepatide functions as a dual agonist targeting both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. By activating GLP-1 receptors, it suppresses appetite and reduces food intake through central nervous system modulation. Concurrently, GIP receptor activation enhances insulin secretion, improves insulin sensitivity, and promotes glucose uptake/utilization, thereby exerting anti-obesity effects via multiple pathways. This review provides a comprehensive theoretical basis for the application of tirzepatide in obesity treatment.